New drug combo takes on deadly brain tumors

NCT ID NCT03423628

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This early-stage study tests an experimental drug called AZD1390 combined with radiation therapy for people with glioblastoma or brain metastases. The main goal is to check safety and find the best dose. About 180 participants will receive different doses of AZD1390 alongside radiation to see how well the combination is tolerated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD1390 (an experimental drug that blocks a protein called ATM, which may help radiation kill cancer cells more effectively)
What this could lead to: If it works, this could point toward a new way to treat aggressive brain tumors by making radiation more effective.
What could go wrong: This is a very early (Phase 1) study, so the main goal is safety, not effectiveness. The drug may not work or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN NEOPLASMS, MALIGNANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer glioblastoma glioma susceptibility 1 hereditary sensory and autonomic neuropathy Inhibition, Psychological Meningeal Neoplasms neoplastic meningitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN NEOPLASMS, MALIGNANT LEPTOMENINGEAL DISEASE (LMD) PRIMARY GLIOBLASTOMA MULTIFORME RECURRENT GLIOBLASTOMA MULTIFORME

Contacts and locations

Locations

Research Site

Boston, Massachusetts, 02114, United States
Research Site

Boston, Massachusetts, 02215, United States
Research Site

New York, New York, 10065, United States
Research Site

Pittsburgh, Pennsylvania, 15232, United States
Research Site

Richmond, Virginia, 23298, United States
Research Site

Chūōku, 104-0045, Japan
Research Site

Hidaka-shi, 350-1298, Japan
Research Site

Kyoto, 606-8507, Japan
Research Site

Cambridge, CB2 0QQ, United Kingdom
Research Site

Glasgow, G12 0YN, United Kingdom
Research Site

Leeds, LS9 7TF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.